Arthneeti

Makers Laboratories Share Price & Earnings Call Analysis

₹201.91-4.00% today
Market cap
₹119 Cr
P/E
34.93
ROE
3.17%
PEG
0.99
Price to sales
0.81
Debt to equity
0.12
52W high / low
₹221 / ₹112
Sales growth (5Y)
15.43%
EBITDA margin
12.59%
Net profit margin
5.41%
Promoter holding
61.28%
Sales (last year)
₹148 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Makers Laboratories rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹480 Cr19.1
240%+Up 0–2%₹212 Cr16.1
340%+Flat₹17,925 Cr—
440%+Flat₹5,223 Cr39.1
540%+Flat₹4,268 Cr—
640%+Flat₹40 Cr—

Sign up free to see every company in the sector ranking and track Makers Laboratories.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Financials of Makers Laboratories

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Makers Laboratories

Quarterly Results

Quarter-by-quarter operating performance

Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales +29.4525.0125.0626.5127.8129.5929.5727.6933.9035.0034.1735.6735.75
Expenses +27.6625.1524.8626.3126.9527.7827.3826.3830.8131.9931.8931.5130.47
Operating Profit1.79-0.140.200.200.861.812.191.313.093.012.284.165.28
OPM %6.08%-0.56%0.80%0.75%3.09%6.12%7.41%4.73%9.12%8.60%6.67%11.66%14.77%
Other Income +0.120.250.410.370.43-0.5110.630.870.100.270.360.330.76
Interest0.250.410.490.530.520.490.430.190.180.180.220.200.17
Depreciation1.131.111.131.161.151.281.291.310.901.121.131.141.13
Profit before tax0.53-1.41-1.01-1.12-0.38-0.4711.100.682.111.981.293.154.74
Tax %33.96%18.44%10.89%-4.46%152.63%48.94%11.98%60.29%24.64%34.85%42.64%27.94%24.89%
Net Profit +0.35-1.66-1.13-1.06-0.97-0.709.760.271.581.290.742.273.56
EPS in Rs-0.47-3.56-2.27-2.61-2.19-1.6614.95-0.51-0.080.75-0.201.591.85

Financials of Makers Laboratories

Profit & Loss

Annual income statement trend

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales +69127101104121141
Expenses +6010898103112126
Operating Profit81931915
OPM %12%15%3%1%7%10%
Other Income +1322112
Interest222211
Depreciation544555
Profit before tax316-1-41311
Tax %50%25%161%23%19%30%
Net Profit +112-2-5118
EPS in Rs-0.568.44-8.05-10.6112.693.98
Dividend Payout %0%0%0%0%0%0%

Financials of Makers Laboratories

Balance Sheet

Capital structure and asset base

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital556666
Reserves495563576567
Borrowings +2123172286
Other Liabilities +626266767088
Total Liabilities136144152161148167
Fixed Assets +716885877471
CWIP090014
Investments2003012
Other Assets +636667717381
Total Assets136144152161148167

Financials of Makers Laboratories

Cash Flows

Operating, investing and financing cash movement

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +018-91-414
Cash from Investing Activity +0-221-720-15
Cash from Financing Activity +0066-160
Net Cash Flow0-3-2-0-0-0
Free Cash Flow09-21-61111
CFO/OP0%128%-185%232%-20%119%

Financials of Makers Laboratories

Ratios

Working capital efficiency and return ratios

Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days883972708452
Inventory Days344166281227230250
Days Payable182389111279109
Cash Conversion Cycle250167262185234192
Working Capital Days1126111397140136
ROCE %15%1%-2%4%9%

Continue your research

Others in Pharmaceuticals & Biotechnology this season

  • Anthem Bioscienc (Q2 FY27)

    Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc

  • Neuland Laboratories (Q2 FY27)

    Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q

  • Hikal (Q2 FY27)

    Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest

  • Kopran (Q2 FY27)

    9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals